Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week

Transplant International

Volumn 25, Issue 11, 2012, Pages 1182-1193

  Barraclough, Katherine A ^a   Staatz, Christine E ^a   Johnson, David W ^a   Lee, Katie J ^a   McWhinney, Brett C ^b   Ungerer, Jacobus P J ^b   Hawley, Carmel M ^a   Campbell, Scott B ^a   Leary, Diana R ^a   Isbel, Nicole M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

immunosuppression; kidney transplantation; mycophenolic acid; prednisolone; tacrolimus

Indexed keywords

BASILIXIMAB; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; DRUG EXPOSURE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEW ONSET DIABETES AFTER TRANSPLANTATION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AREA UNDER CURVE; DELAYED GRAFT FUNCTION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS; TREATMENT OUTCOME;

EID: 84867507684     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01553.x     Document Type: Article

References (70)

1. Australia and New Zealand Dialysis and Transplant Registry. http://www.anzdata.org.au/anzdata/AnzdataReport/33rdReport/Ch08.pdf (Accessed October 20, 2011).
2. U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. http://www.ustransplant.org/annual-reports/ current/109a-dh.htm (Accessed October 20, 2011).
3. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B,. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
4. Chang SH, Russ GR, Chadban SJ, Campbell SB, McDonald SP,. Trends in kidney transplantation in Australia and New Zealand, 1993-2004. Transplantation 2007; 84: 611.
5. US Renal Data System: USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2006: 147.
6. McDonald S, Russ G, Campbell S, Chadban S,. Kidney transplant rejection in Australia and New Zealand: relationships between rejection and graft outcome. Am J Transplant 2007; 7: 1201.
7. Ashton-Chess J, Giral M, Soulillou JP, Brouard S,. Can immune monitoring help to minimize immunosuppression in kidney transplantation? Transpl Int 2009; 22: 110.
8. Staatz CE, Tett SE,. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623.
9. Tada H, Satoh S, Iinuma M, et al. Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. J Clin Pharmacol 2003; 43: 859.
10. Braun F, Schutz E, Peters B, et al. Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. Transplant Proc 2001; 33: 2127.
11. Kimikawa M, Kamoya K, Toma H, Teraoka S,. Effective oral administration of tacrolimus in renal transplant recipients. Clin Transplant 2001; 15: 324.
12. Pisitkun T, Eiam-Ong S, Chusil S, Praditpornsilpa K, Pansin P, Tungsanga K,. The roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients. Transplant Proc 2002; 34: 3173.
13. Bottiger Y, Undre NA, Sawe J, Stevenson PJ, Ericzon BG,. Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. Transplant Proc 2002; 34: 1544.
14. Wong KM, Shek CC, Chau KF, Li CS,. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis 2000; 35: 660.
15. Stolk LM, Van Duijnhoven EM, Christiaans MH, Van Hooff JP,. Trough levels of tacrolimus. Ther Drug Monit 2002; 24: 573. author reply -4.
16. Mathew BS, Fleming DH, Jeyaseelan V, et al. A limited sampling strategy for tacrolimus in renal transplant patients. Br J Clin Pharmacol 2008; 66: 467.
17. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281.
18. Jorgensen K, Povlsen J, Madsen S, et al. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant 2002; 17: 1487.
19. Cantarovich M, Fridell J, Barkun J, et al. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. Transplant Proc 1998; 30: 1460.
20. Armendariz Y, Pou L, Cantarell C, Lopez R, Perello M, Capdevila L,. Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit 2005; 27: 431.
21. Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ,. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 62: 900.
22. Undre NA, Van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999; 31: 296.
23. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
24. Ekberg H, Bernasconi C, Noldeke Jea,. Cyclosporine, tacrolimus, and sirolimus retained their distinct toxicity profiles despite low doses in the Symphony study (abstract). Am J Transplant 2007; 7 (Suppl. 2): 160.
25. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009; 31: 139.
26. Barraclough KA, Isbel NM, Staatz CE,. Evaluation of the mycophenolic acid exposure estimation methods used in the APOMYGERE, FDCC, and Opticept trials. Transplantation 2010; 90: 44.
27. Barraclough KA, Staatz CE, Isbel NM, Johnson DW,. Therapeutic monitoring of mycophenolate in transplantation: is it justified? Curr Drug Metab 2009; 10: 179.
28. Gaston RS, Kaplan B, Shah T, et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the opticept trial. Am J Transplant 2009; 9: 1607.
29. Le MeurY, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496.
30. Van Gelder T, Silva H, De Fijter H, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008; 86: 1043.
31. Shaw LM, Kaplan B, DeNofrio D, Korecka M, Brayman KL,. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit 2000; 22: 14.
32. Van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261.
33. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64: 672.
34. Gourishankar S, Houde I, Keown PA, et al. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Clin J Am Soc Nephrol 2010; 5: 1282.
35. Barraclough KA, Isbel NM, McWhinney BC, et al. Evaluation of limited sampling strategies for total and free prednisolone in adult kidney transplant recipients. Eur J Clin Pharmacol 2011; 67: 1243.
36. Morton JM, Williamson S, Kear LM, McWhinney BC, Potter J, Glanville AR,. Therapeutic drug monitoring of prednisolone after lung transplantation. J Heart Lung Transplant 2006; 25: 557.
37. Potter JM, McWhinney BC, Sampson L, Hickman PE,. Area-under-the-curve monitoring of prednisolone for dose optimization in a stable renal transplant population. Ther Drug Monit 2004; 26: 408.
38. Ost L, Bjorkhem I, Von Bahr C,. Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation. Eur J Clin Pharmacol 1984; 26: 363.
39. Available at: http://www.halls.md/ideal-weight/devine.htm (Accessed June 12, 2012).
40. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518.
41. Australia and New Zealand Dialysis and Transplant Registry. http://www.anzdata.org.au/documents/pdf/ANZDATADictionary2011Feb.pdf. (Accessed October 12, 2011).
42. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an International Expert Panel Meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003; 10 (Suppl.): SS3.
43. Barraclough KA, Isbel NM, Kirkpatrick CM, et al. Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. Br J Clin Pharmacol 2011; 71: 207.
44. Barraclough KA, Isbel NM, Franklin ME, et al. Evaluation of limited sampling strategies for mycophenolic acid after mycophenolate mofetil intake in adult kidney transplant recipients. Ther Drug Monit 2010; 32: 723.
45. Staatz CE, Tett SE,. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007; 46: 13.
46. Vogt M, Derendorf H, Kramer J, et al. Biowaiver monographs for immediate release solid oral dosage forms: prednisolone. J Pharm Sci 2007; 96: 27.
47. Taylor PJ, Brown SR, Cooper DP, Lynch SV, Pi P,. A high-throughput HPLC-MS/MS method for tacrolimus measurement (abstract). Ther Drug Monit 2005; 27: 256.
48. Keevil BG, McCann SJ, Cooper DP, Morris MR,. Evaluation of a rapid micro-scale assay for tacrolimus by liquid chromatography-tandem mass spectrometry. Ann Clin Biochem. 2002; 39: 487.
49. Brown NW, Franklin ME, Einarsdottir EN, et al. An investigation into the bias between liquid chromatography-tandem mass spectrometry and an enzyme multiplied immunoassay technique for the measurement of mycophenolic acid. Ther Drug Monit 2010; 32: 420.
50. McWhinney BC, Briscoe SE, Ungerer JP, Pretorius CJ,. Measurement of cortisol, cortisone, prednisolone, dexamethasone and 11-deoxycortisol with ultra high performance liquid chromatography-tandem mass spectrometry: application for plasma, plasma ultrafiltrate, urine and saliva in a routine laboratory. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 2863.
51. Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766.
52. Kuypers DR, Meur YL, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010; 5: 341.
53. Staatz CE, Goodman LK, Tett SE,. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 2010; 49: 141.
54. Naesens M, De Loor H, Vanrenterghem Y, Kuypers DR,. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation 2007; 84: 362.
55. Hanada K, Ogawa R, Son K, et al. Effects of indoxylsulfate on the in vitro hepatic metabolism of various compounds using human liver microsomes and hepatocytes. Nephron Physiol 2006; 103: p179.
56. Magee MH, Blum RA, Lates CD, Jusko WJ,. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol 2001; 41: 1180.
57. Bergrem H,. Pharmacokinetics and protein binding of prednisolone in patients with nephrotic syndrome and patients undergoing hemodialysis. Kidney Int 1983; 23: 876.
58. Bergrem H,. The influence of uremia on pharmacokinetics and protein binding of prednisolone. Acta Med Scand 1983; 213: 333.
59. Jusko WJ, Rose JQ,. Monitoring prednisone and prednisolone. Ther Drug Monit 1980; 2: 169.
60. Scholten EM, Cremers SC, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 2005; 67: 2440.
61. Kuypers DR, De Jonge H, Naesens M, Vanrenterghem Y,. A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. Clin Ther 2010; 32: 2012.
62. Sun H, Frassetto LA, Huang Y, Benet LZ,. Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin Pharmacol Ther 2010; 87: 465.
63. Nolin TD, Frye RF, Le P, et al. ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol 2009; 20: 2269.
64. Budde K, Tedesco-Silva H, Arns W, et al. Improved rejection prophylaxis with an initially intensified dosing regimen of enteric-coated mycophenolate sodium in de novo renal transplant recipients. Transplantation 2011; 92: 321.
65. Bergrem H, Jervell J, Flatmark A,. Prednisolone pharmacokinetics in cushingoid and non-cushingoid kidney transplant patients. Kidney Int 1985; 27: 459.
66. Bergrem HA, Bergrem H, Hartmann A, Hjelmesaeth J, Jenssen T,. Role of prednisolone pharmacokinetics in postchallenge glycemia after renal transplantation. Ther Drug Monit 2008; 30: 583.
67. Frey BM, Frey FJ,. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 1990; 19: 126.
68. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P,. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564.
69. Kuypers DR, Claes K, Evenepoel P, et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 2003; 43: 866.
70. Sharif A, Moore RH, Baboolal K,. The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: an underdiagnosed phenomenon. Transplantation 2006; 82: 1667.